Expert Consensus on the Diagnosis and Treatment of Acute Intermittent Porphyria in China

Title: Expert Consensus on the Diagnosis and Treatment of Acute Intermittent Porphyria in China
Edition: Original
Classification: Standard guideline
Field: Diagnosis and Treatment
Countries and regions: China
Guidelines users: This consensus is used by the majority of clinical practitioners, such as endocrinology and metabolism department, emergency department, gastroenterology department, intensive care medicine department, neurology department, etc., suitable for acute intermittent porphyria patients.
Evidence classification method: Based on the GRADE approach, the quality of evidence was subdivided into high, medium, low, and very low levels based on risk of bias, accuracy, incoherence, interstudy inconsistencies, and publication bias. The recommendation level is divided into two categories: strong recommendation and weak recommendation.
Development unit: Chinese Society of Rare Diseases Study Group of Endocrinology Rare Diseases, Chinese Society of Endocrinology Chinese Pharmacists Association Rare Diseases Medication Working Committee
Registration time: 2024-09-28
Registration number: PREPARE-2024CN681
Purpose of the guideline: It will form a consensus on the diagnosis, treatment, evaluation and prevention of acute intermittent porphyria, and provide a basis for standardized clinical diagnosis and treatment.